Background: The present work aimed to evaluate radio-genomic associations of quantitative parameters obtained by dual-energy spectral computed tomography (DESCT) for solid lung adenocarcinoma with epidermal growth factor receptor (EGFR) and Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations, as well as anaplastic lymphoma kinase (ALK) rearrangement.
Introduction
As the main histological subtype of pulmonary cancer, adenocarcinoma is considered a heterogeneous malignancy based on molecular features (1, 2) . A recent study demonstrated that patients with lung adenocarcinoma can be treated by novel therapeutics targeting signaling pathways (3) . Moreover, precise characterization of lung adenocarcinoma at the genetic level is a fundamental requirement for personalized therapy targeting the involved driver oncogenes.
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Transl Lung Cancer Res 2019;8(4):401-412 | http://dx.doi.org/10.21037/tlcr.2019.08 .13 In general, there are several genetic causes of lung adenocarcinoma, including the most common mutations of the three genes epidermal growth factor receptor (EGFR), Kirsten rat sarcoma viral oncogene homolog (KRAS) and anaplastic lymphoma kinase (ALK). Among these three genes, the EGFR oncogene has been widely assessed, therefore becoming a well-established therapeutic target. Studies have shown that tyrosine kinase inhibitors (TKIs) targeting EGFR can effectively treat lung carcinoma, improving patient outcome compared with standard platinum-based chemotherapy (4, 5) . KRAS, a Ras GTPase, was first described as a cell growth and division inducer, but is currently considered a non-drug target with insufficient response to standard and targeted therapies (6) . ALK has attracted considerable attention recently from scientists (7, 8) . Lung cancer with ALK rearrangement is considered a subgroup that shows a striking response to specific targeted drugs, including crizotinib (9, 10) , which have had approval from the US and Chinese Food and Drug Administrations in 2011 and 2013, respectively (11, 12) . In the latest guidelines from 2018 by the College of American Pathologists/International Association for the Study of Lung Cancer/Association of Molecular Pathology, the EGFR and ALK genes must be tested in pulmonary cancer, while KRAS is a recommended test gene, especially in cases where routine tests for EGFR and ALK show negative results (13) .
In clinical practice, it is crucial to identify the oncogene status, in order to molecularly categorize lung adenocarcinoma. Computed tomography (CT) is considered the starkest modality for diagnosing lung diseases before surgery. In recent radio-genomics studies, one of the main research aspects has been to explore the relationships between imaging and molecular phenotypes (14) . A few studies have explored the possible associations of gene mutations with conventional CT imaging features in order to categorize subclasses of lung adenocarcinoma (15) (16) (17) (18) (19) (20) (21) (22) (23) . However, conventional CT imaging features are not quantitative, making them vulnerable to the subjectivity of visual judgment. It is now widely recognized that the ground-glass opacity (GGO) ratio is remarkably high in tumors with EGFR mutations (15) (16) (17) , and tumors with ALK rearrangement are usually solid nodules (19) (20) (21) (22) . However, it remains difficult to identify the oncogene status of solid tumors by conventional CT. Meanwhile, identification of the oncogene status is very crucial for patients with solid lung adenocarcinoma, because targeted treatments generally focus on solid tumors in the advanced stage.
In dual-energy spectral CT (DESCT), two consistent energy data sets are generated by the fast-kVp switching technology at 80-140 kVp. Then, monochromatic images are generated from 40 to 140 keV via projection-based reconstruction, which provides quantitative information about different materials (calcium, iodine, water, fat, etc.) based on unique linear attenuation coefficients (24) . Therefore, the most prominent advantages of DESCT over conventional CT comprise its set of quantitative analysis tools as well as integrated diagnostic methodology based on multi-parameter images, including material-decomposition images, monochromatic images and spectral curves. DESCT has the potential for characterizing different materials based on elemental composition. Accumulating evidence indicates that DESCT can be employed as a potential diagnostic method in almost all human systems (25) (26) (27) (28) (29) (30) (31) (32) (33) . With respect to the lung, DESCT has been used for differential diagnosis of tumors from benign lung disease, detecting lymph node metastasis and distinguishing histological subtypes (34), with higher accuracy than conventional CT.
However, studies assessing the associations of DESCT's quantitative parameters with the most commonly encountered genetic mutations in solid lung adenocarcinoma are scarce. Therefore, this work was designed to retrospectively assess DESCT's feasibility for preoperative identification of EGFR, KRAS and ALK status in Chinese cancer cases using the available results for surgically resected solid lung adenocarcinomas.
Methods
The current study was approved by the institutional ethics committee of Cancer Hospital, Chinese Academy of Medical Sciences (No. NCC2016G-029), with waived written informed consent due to anonymous data analysis.
Patient selection
From May 2013 to December 2015, a total of 1,010 patients were retrospectively enrolled from a prospectively collected database of lung nodules and masses. The study group underwent pretreatment chest DESCT at the authors' institution with the following inclusion criteria: presence of solid nodule(s) or mass(es) on CT imaging; histopathological diagnosis of adenocarcinoma. EGFR and KRAS mutations as well as ALK rearrangement were detected after surgery or biopsy at the authors' institution ( Figure 1 ).
DESCT examination
DESCT was carried out on a Discovery CT 750 HD scanner (GE Healthcare, USA) as follows: Gemstone Spectral Imaging (GSI) mode; tube current, 550 mA; rotation time, 0.6 s; pitch value of 0.984 in the helical mode; field of view (FOV), large body; slice interval and thickness for each axial image of 0.8 and 1.25 mm, respectively. Scanning was performed from the lung apex to adrenal glands. Data acquisition was initiated after a delay of 35 s. Cases were intravenously administered 85-100 mL (1.5 mL/kg) of contrast media (Ultravist 300; Bayer Pharma AG) at 2.5 mL/s.
Quantitative analysis of DESCT data
A set of material decomposition (MD) images (iodine/water) and monochromatic images were reconstructed from the original spectral data. Then, GSI Volume Viewer on the post-processing workstation (Advantage Workstation 4.6, GE Healthcare, Milwaukee, WI, USA) was used to analyze the reconstructed images to obtain DESCT's quantitative data.
In order to eliminate the effect of air surrounding the tumors, a mediastinum window (Width =350, Level =50) was used to measure the tumors in axial images. Then, the axial CT slice was selected by an experienced radiologist to depict the maximum diameter of the primary tumor for CT diagnosis of chest tumors. The region of interest (ROI) was selected in the lesion center with a range of less than 2/3 of the total lesion area. The effective atomic number (Effective-Z) of the lesion was recorded from the effective atomic number image. Water concentration (WC) and iodine concentration (IC) were determined from water and iodine-based MD images, respectively. In addition, spectral Hounsfield unit curve slope (λHU slope) was calculated by the following equation: λHU slope = (CT 40 keV − CT 100 keV)/(100−40). Meanwhile, the enhanced CT value in monochromatic images at 70 keV (CT value at 70 keV) was selected since conventional 120 kVp polychromatic images have similar mean energy values as 70 keV GSI images. Therefore, quantitative data included CT value at 70 keV, IC, WC, Effective-Z, and λHU slope. 
Analysis of tumor EGFR and KRAS mutations, and ALK rearrangement
The patients' histologic assessment and mutation analyses for the three oncogenes were performed by pathological examinations of surgical (including radical surgery and palliative operation) or biopsy specimens. The mutation status of EGFR or KRAS was examined by molecular pathological analysis. ALK gene rearrangement was detected by immunohistochemistry (IHC).
Statistical analysis
Continuous patient and DESCT variables with normal distribution were expressed as mean ± standard deviation (X ± SD 
Results

Features of the patients and oncogenes
According to inclusion criteria, 96 patients with solid lung adenocarcinoma (48 men and 48 women averaging 58 years old) submitted to DESCT scanning and EGFR, KRAS and ALK testing after surgery (85 and 7 patients underwent radical and palliative operations, respectively) or biopsy (4 cases) were recruited. The detailed information of the study population is summarized in 
Radio-genomic association of DESCT with EGFR mutation
As shown in (Figure 2) . Figure 2E shows EGFR mutation prediction based on ROC curves, and the AUC of all factors combined was 0.753.
Radio-genomic association of DESCT with KRAS mutation
As shown in Table 2 , besides smoking status (P=0.024), univariate analysis revealed cases harboring KRAS mutations presented associations with DESCT quantitative parameters, including CT value at 70 keV, IC, Effective-Z and λHU slope (P=0.008, P=0.014, P=0.005 and P=0.014, respectively). Multivariate analysis showed that only Effective-Z (OR =0.047, P=0.032) was significantly correlated with KRAS mutations (Figure 3) . Figure 3E shows KRAS mutation prediction in ROC curves, and the AUC of the full model was 0.832. Table 3 shows that patients with ALK rearrangement had younger age (clinical feature) and lower WC in univariate analysis (Figure 4) . Multivariate analysis showed that only age (OR =0.933, P=0.008) was significantly associated with ALK rearrangement. Figure 4E shows ALK rearrangement prediction in ROC curves, and the AUC of the full model was 0.748.
Radio-genomic association of DESCT with ALK rearrangement
Discussion
E G F R , K R A S a n d A L K g e n e a l t e r a t i o n s w e r e detected in 51.0% (49/96), 13.5% (13/96), and 16.7% (16/96) patients with solid lung adenocarcinomas, respectively, in the present work. The high EGFR mutation rate reflects the genetic characteristic of the East Asian ethnic group, which is completely different from the Western population (4, 5, 35, 36) . In contrast, the prevalence of the KRAS mutation seems much lower in the East Asian population (37) . KRAS mutation and ALK rearrangement rates in this study were higher than those previously reported (7, (38) (39) (40) . This could be explained by that all patients included in this study had solid adenocarcinomas; indeed, lung adenocarcinomas with KRAS mutation and ALK rearrangement commonly present as solid nodules with no GGO (20) (21) (22) . In the present cohort, no patient had two or more gene mutations simultaneously, as these mutations are mutually exclusive. The current study observed notable associations of EGFR mutation with DESCT quantitative indexes, including CT value at 70 keV, IC, Effective-Z and λHU slope in univariate analysis. Meanwhile, only CT value at 70 keV was significantly associated with the above mutation in multivariable analysis. In patients with EGFR mutations, CT values at 70 keV were markedly elevated compared with those of cases harboring wild type EGFR. In addition to its role in cancer genesis and development, EGFR is involved in both pathological and physiological angiogenetic processes through its effects on both tumor and endothelial cells (41) . Furthermore, EGFR can upregulate hypoxia-inducible factor α, increasing the expression and secretion levels of angiogenic proteins, including vascular endothelial growth factor, thereby stimulating angiogenesis (42) . Increased angiogenesis could augment blood supply to the site, which would in turn enhances detection by DESCT. This indicates that DESCT could distinguish different EGFR statuses in lung adenocarcinoma. Next, the known association of EGFR mutation with the non-smoking status was verified by univariable and multivariable analyses. In this study, women showed an elevated rate of EGFR mutations, but the difference was not statistically significant, likely because of the relatively small number of patients assessed. The ROC obtained after combining the significant factors showed a moderate predictive value for EGFR mutation identification (AUC =0.753). KRAS mutations constitute negative prognostic markers in lung adenocarcinoma patients. However, the association of conventional CT imaging with KRAS mutation in lung adenocarcinoma is not significant (43) . In contrast, KRAS mutation and DESCT quantitative parameters, such as CT value at 70 keV, IC, Effective-Z and λHU slope, had significant associations in univariate analysis, as shown above. Meanwhile, only Effective-Z remained significant in multivariate analysis. Lung adenocarcinomas harboring KRAS mutations have specific pathological features. In terms of histology, KRAS mutations are more associated with mucinous adenocarcinoma or lung cancer showing goblet cell morphology compared with non-mucinous adenocarcinoma (44) (45) (46) . We speculate that DESCT findings might correlate with the underlying pathologic appearance. The mucus produced by KRAS mutant adenocarcinoma may result in a lower quantitative value. As shown above, the ROC obtained by combining all significant factors revealed a moderate predictive value in EGFR mutation identification (AUC =0.832). 230  220  210  200  190  180  170  160  150  140  130  120  110  100  90  80  70  60  50  40 Until recently, fluorescence in situ hybridization (FISH) was considered the standard method for ALK status testing; however, this technique is not widely applicable due to high cost and long testing time (47, 48) . Instead, IHC has been intensively used as a screening tool due to easy implementation and affordability for most patients (49) . Thus, the latest guidelines state that IHC could replace FISH as the gold standard (13) . A recent study indicated that ALK positive lung adenocarcinomas testing positive in IHC and negative in FISH might still be successfully treated with crizotinib (50). Therefore, IHC was applied as the gold standard for assessing the ALK status in the current study. The above results confirmed that tumors with ALK rearrangement had preference for younger age, both by univariate and multivariate analyses. However, in the current study, no DESCT's quantitative parameter of the primary tumor was significantly associated with ALK rearrangement in multivariate analyses. WC and CT values at 70 keV were lower in lung adenocarcinoma with ALK rearrangement, and WC showed statistical significance (P=0.028). DESCT findings might correlate with the underlying pathologic appearance. Studies showed ALK rearrangement mostly occurs in a solid growth pattern with signet-ring cells (51, 52) . We speculate that WC is reduced in adenocarcinoma with ALK rearrangement because less extracellular fluid fills the intercellular space than observed in other subtypes. The ROC obtained by combining all significant factors (including CT value at 70 keV) also showed a moderate predictive value in EGFR mutation identification (AUC =0.748).
A B
This study had several limitations. First, the sample size was relatively small, especially the number of cases harboring KRAS mutations and ALK rearrangement. This was due to the low prevalence rates of these mutations. Therefore, the current results must be validated in a larger, multi-institutional cohort. Secondly, most adenocarcinoma patients assessed were candidates for surgical resection, which may result in selection bias toward more preadvanced cases. Thirdly, many conventional CT features, such as GGO, cavity, bubble-like lucency, and air bronchogram were scarce because all the patients included in this study presented solid lung adenocarcinomas. Moreover, some important non-quantitative conventional CT features, such as spiculation and pleural retraction, were not considered in this study.
Conclusions
Overall, this preliminary radio-genomics study is the first to reveal that quantitative analysis of DESCT has the potential to predict EGFR and KRAS mutations as well as ALK rearrangement in cases with solid lung adenocarcinomas. Compared with other molecular-level technologies, DESCT can provide a comprehensive approach to evaluate the entire tumor non-invasively, which may be incorporated for decision-making in precise diagnosis.
